Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 454 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle solution Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

NCT04657172
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic, Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Azusa, California • Newport Beach, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

NCT05646719
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Opthalmic Solution 0.75%, Placebo, Low dose pilocarpine, Low dose pilocarpine vehicle
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
40 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Azusa, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00651859
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 20, 2026, 2:08 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults

NCT07531043
View directory record Official record
Conditions
Ocular Hyperemia
Interventions
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Newport Beach, California • Pittsburg, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Results available

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

NCT05505292
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

NCT05493111
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Chandler, Arizona • Sun City, Arizona • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Terminated Early Phase 1 Interventional

Intratumoral Microdosing of Motolimod in HNSCC

NCT04272333
View directory record Official record
Conditions
HNSCC
Interventions
Motolimod, Nivolumab, Motolimod + Nivolumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 20, 2026, 2:08 AM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

NCT05802173
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
North Little Rock, Arkansas • Rolling Meadows, Illinois • Plainfield, Indiana + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face

NCT02632110
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Topical Solution Vehicle, IBL 10 mW, Microneedle lesion preparation, IBL 20 mW
Drug · Device · Procedure
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
San Diego, California • Brandon, Florida • Arlington Heights, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 4 Interventional Results available

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

NCT01448525
View directory record Official record
Conditions
Hypotrichosis
Interventions
bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients

NCT04276558
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
Udonitrectag, Vehicle
Drug · Other
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
9
States / cities
Crystal River, Florida • Gainesville, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 2 Interventional

Next Generation Rocklatan

NCT06441643
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution, Netarsudil 0.02% Ophthalmic Solution, Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, AR-17043 Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Garden Grove, California • Inglewood, California • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Suspended Phase 2 Interventional

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

NCT05067257
View directory record Official record
Conditions
Pain, Intractable, Pain Cancer, Pain
Interventions
Resiniferatoxin, Placebo
Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
La Jolla, California • Gainesville, Florida • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis

NCT02965781
View directory record Official record
Conditions
Herpes Labialis, Cold Sore
Interventions
SADBE, Placebo
Drug · Other
Lead sponsor
Squarex, LLC
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 20, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Moxidex Otic

NCT01071902
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Moxidex otic solution, Moxifloxacin otic solution, Vehicle, Tympanostomy tubes
Drug · Other · Device
Lead sponsor
Alcon Research
Industry
Eligibility
6 Months to 12 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 20, 2026, 2:08 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

NCT05360966
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Chico, California • Fullerton, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers

NCT02227069
View directory record Official record
Conditions
Healthy Volunteers
Interventions
M518101, M518101 Vehicle, sodium lauryl sulfate, saline
Drug · Other
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Early Phase 1 Interventional

Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)

NCT02710162
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Micro Mouth Pressure Meter, Iowa Oral Performance Instrument, Electrical Impedance Myography, Capsaicin, Videofluoroscopic Swallowing Study, Pulmonary Function Testing, Swallowing Related Quality of Life Questionnaire, Functional Oral Intake Scale, Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised, Eating Assessment Tool-10, Communicative Effectiveness Survey, The Center for Neurologic Studies Bulbar Function Scale
Device · Drug · Procedure + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 20, 2026, 2:08 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226759
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 20, 2026, 2:08 AM EDT